CA2521529A1 - Irm-support complexes comprising immune response modifiers attached to macromolecular support material - Google Patents
Irm-support complexes comprising immune response modifiers attached to macromolecular support material Download PDFInfo
- Publication number
- CA2521529A1 CA2521529A1 CA002521529A CA2521529A CA2521529A1 CA 2521529 A1 CA2521529 A1 CA 2521529A1 CA 002521529 A CA002521529 A CA 002521529A CA 2521529 A CA2521529 A CA 2521529A CA 2521529 A1 CA2521529 A1 CA 2521529A1
- Authority
- CA
- Canada
- Prior art keywords
- irm
- amines
- support complex
- immune response
- support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000463 material Substances 0.000 title claims abstract 17
- 230000028993 immune response Effects 0.000 title claims abstract 15
- 239000003607 modifier Substances 0.000 title claims abstract 14
- -1 IRM compound Chemical class 0.000 claims 54
- 238000000034 method Methods 0.000 claims 24
- 229940124669 imidazoquinoline Drugs 0.000 claims 6
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims 4
- 102000002689 Toll-like receptor Human genes 0.000 claims 4
- 108020000411 Toll-like receptor Proteins 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 230000006698 induction Effects 0.000 claims 3
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 2
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- 150000001556 benzimidazoles Chemical class 0.000 claims 2
- 239000004053 dental implant Substances 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 238000001631 haemodialysis Methods 0.000 claims 2
- 230000000322 hemodialysis Effects 0.000 claims 2
- 230000001951 hemoperfusion Effects 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000000399 orthopedic effect Effects 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 238000002616 plasmapheresis Methods 0.000 claims 2
- 150000003212 purines Chemical class 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N tetrahydroquinoline Natural products C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008263 Cervical dysplasia Diseases 0.000 claims 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000000227 bioadhesive Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940097134 periochip Drugs 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract 2
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention provides immune response modifiers (IRMs) associated with (typically, attached to, and preferably, covalently attached to) macromolecular support materials. The IRM compounds in such IRM-support complexes retain biological activity. Such attachment of an IRM to a macromolecular support material provides for the localized biological activity of the IRM.
Claims (51)
1. An IRM-support complex comprising an IRM compound attached to a macromolecular support material.
2. The IRM-support complex of claim 1, wherein the IRM compound is covalently attached to the macromolecular support material.
3. The IRM-support complex of claim 1, wherein the macromolecular support material is selected from the group consisting of a gel, a foam, a sponge, a fiber, a hydrogel, and a bead.
4. The IRM-support complex of claim 1, wherein the IRM compound is an agonist of at least one TLR.
5. The IRM-support complex of claim 4, wherein the TLR is selected from the group consisting of TLR6, TLR7, TLR8, and combinations thereof.
6. The IRM-support complex of claim 1, wherein the IRM compound is a small molecule immune response modifier.
7. The IRM-support complex of claim 1, wherein the IRM compound is selected from the group consisting of imidazoquinoline amines; tetrahydroimidazoquinoline amines;
and imidazopyridine amines; 1,2-bridged imidazoquinoline amines; 6,7-fused cycloalkylimidazopyridine amines; imidazonaphthyridine amines;
tetrahydroimidazonaphthyridine amines; oxazoloquinoline amines;
thiazoloquinoline amines; oxazolopyridine amines; thiazolopyridine amines; oxazolonaphthyridine amines; thiazolonaphthyridine amines; 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines; and combinations thereof.
and imidazopyridine amines; 1,2-bridged imidazoquinoline amines; 6,7-fused cycloalkylimidazopyridine amines; imidazonaphthyridine amines;
tetrahydroimidazonaphthyridine amines; oxazoloquinoline amines;
thiazoloquinoline amines; oxazolopyridine amines; thiazolopyridine amines; oxazolonaphthyridine amines; thiazolonaphthyridine amines; 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines; and combinations thereof.
8. The IRM-support complex of claim 1, wherein the IRM compound is selected from the group consisting of purines, imidazoquinoline amides, benzimidazoles, 1H-imidazopyridines, adenines, and derivatives thereof.
9. The IRM-support complex of claim 1, wherein the IRM compound comprises a 2-aminopyridine fused to a five-membered nitrogen-containing heterocyclic ring.
10. The IRM-support complex of claim 1, wherein the IRM compound comprises a 4-aminopyrimidine fused to a five-membered nitrogen containing heterocyclic ring.
11. The IRM-support complex of claim 1, wherein the macromolecular support material has an average largest dimension of at least 1 nm.
12. An IRM-support complex comprising an immune response modifier attached to a polymer.
13. The IRM-support complex of claim 12, wherein the immune response modifier is covalently attached to the polymer.
14. The IRM-support complex of claim 13, wherein the polymer is a bioadhesive polymer.
15. A medical article coated with the IRM-support complex of claim 12.
16. A medical article comprising an IRM-support complex, wherein the IRM-support complex comprises an IRM compound attached to a macromolecular support material.
17. The medical article of claim 16, wherein the medical article is selected from the group consisting of a stent, a shunt, an artificial valve, a suture, a surgical clip, a surgical staple, an indwelling catheter, a dental implant, an orthopedic implant, a surgical prosthetic, an implantable vascular access port, an artificial heart, a ventricular assist pump, a blood oxygenator, a blood filter, a hemodialysis unit, a hemoperfusion unit, a conduit tube within a heart lung machine, a tube within a dialysis apparatus, a tube within a plasmapheresis unit, an artificial pancreas, an artificial liver, an artificial lung, an intraocular lens, and a contact lens.
18. The medical article of claim 17 which is an implantable device.
19. A stent, shunt, or valve comprising a surface having an immune response modifier attached thereto.
20. The stent, shunt, or valve of claim 19, wherein the immune response modifier is covalently attached to the surface of the stent, shunt, or valve.
21. A medical article having disposed thereon an IRM, with the proviso that the medical article is not a periochip.
22. The medical article of claim 21 selected from the group consisting of a stent, a shunt an artificial valve, a suture, a surgical clip, a surgical staple, an indwelling catheter, a dental implant, an orthopedic implant, a surgical prosthetic, an implantable vascular access port, an artificial heart, a ventricular assist pump, a blood oxygenator, a blood filter, a hemodialysis unit, a hemoperfusion unit, a conduit tube within a heart lung machine, a tube within a dialysis apparatus, a tube within a plasmapheresis unit, an artificial pancreas, an artificial liver, an artificial lung, an intraocular lens, and a contact lens.
23. The medical article of claim 22 which is a stent.
24. A formulation comprising an IRM-support complex comprising a first immune response modifier that is attached to a macromolecular support.
25. The formulation of claim 24 further comprising a second immune response modifier that is not attached to the macromolecular support material.
26. The formulation of claim 24 further comprising a solvent.
27. The formulation of claim 24 which is in the form of a gel.
28. A method of making an IRM-support complex comprising attaching an immune response modifier to a macromolecular support material.
29. The method of claim 28, wherein the immune response modifier is covalently attached to the macromolecular support material.
30. The method of claim 28, wherein the method comprises modifying the IRM to comprise an alkoxysilane moiety.
31. The method of claim 30, wherein the IRM-modified alkoxysilane is attached to a silicon-containing support material.
32. A method of treating a viral infection in a subject comprising administering to the subject an IRM-support complex of claim 1.
33. The method of claim 32, wherein the IRM-support complex is administered orally, nasally, ocularly, vaginally, transcutaneously, or rectally.
34. A method of treating an atopic immune response in a subject comprising administering to the subject an IRM-support complex of claim 1.
35. The method of claim 34, wherein the IRM-substrate is administered orally, nasally, vaginally, ocularly, transcutaneously, or rectally.
36. A method of preventing the restenosis in a subject comprising implanting into the subject a stent having an IRM attached thereto.
37. A method of preventing the restenosis in a subject comprising implanting into the subject a stent having an IRM disposed thereon.
38. The method of claim 37, wherein the IRM compound is an agonist of at least one TLR.
39. The method of claim 38, wherein the TLR is selected from the group consisting of TLR6, TLR7, TLR8, and combinations thereof.
40. The method of claim 37, wherein the IRM compound is a small molecule immune response modifier.
41. The method of claim 37, wherein the IRM compound is selected from the group consisting of imidazoquinoline amines; tetrahydroimidazoquinoline amines; and imidazopyridine amines; 1,2-bridged imidazoquinoline amines; 6,7-fused cycloalkylimidazopyridine amines; imidazonaphthyridine amines;
tetrahydroimidazonaphthyridine amines; oxazoloquinoline amines;
thiazoloquinoline amines; oxazolopyridine amines; thiazolopyridine amines; oxazolonaphthyridine amines; thiazolonaphthyridine amines; 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines; and combinations thereof.
tetrahydroimidazonaphthyridine amines; oxazoloquinoline amines;
thiazoloquinoline amines; oxazolopyridine amines; thiazolopyridine amines; oxazolonaphthyridine amines; thiazolonaphthyridine amines; 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines; and combinations thereof.
42. The method of claim 37, wherein the IRM compound is selected from the group consisting of purines, imidazoquinoline amides, benzimidazoles, 1H-imidazopyridines, adenines, and derivatives thereof.
43. The method of claim 37, wherein the IRM compound comprises a 2-aminopyridine fused to a five-membered nitrogen-containing heterocyclic ring.
44. The method of claim 37, wherein the IRM compound comprises a 4-aminopyrimidine fused to a five-membered nitrogen containing heterocyclic ring.
45. A method of modifying the cytokine induction profile of an IRM by attaching the IRM to a macromolecular support complex.
46. The method of claim 45, wherein the cytokine induction profile is modified in favor of interferon a induction.
47. A method of preventing systemic adsorption of an immune response modifier by a subject comprising administering to the subject an IRM-support complex comprising said immune response modifier attached to a macromolecular support material.
48. A method of activating dendritic cells by permitting the cells contact an IRM .
compound attached to a macromolecular support material.
compound attached to a macromolecular support material.
49. A method of treating solid tumors in a subject comprising administering to the subject an IRM-support complex comprising an IRM compound attached to a macromolecular support material.
50. A method of treating cervical dysplasia in a subject comprising applying to the cervix an IRM-support complex comprising an IRM compound attached to a macromolecular support material.
51. A method of treating bladder cancer in a subject comprising applying to the bladder an IRM support complex comprising an IRM compound attached to a macromolecular support material.
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46214003P | 2003-04-10 | 2003-04-10 | |
| US60/462,140 | 2003-04-10 | ||
| US10/640,904 US7427629B2 (en) | 2002-08-15 | 2003-08-14 | Immunostimulatory compositions and methods of stimulating an immune response |
| US10/640,904 | 2003-08-14 | ||
| US10/640,904(CIP) | 2003-08-14 | ||
| US51525603P | 2003-10-29 | 2003-10-29 | |
| US60/515,256 | 2003-10-29 | ||
| US54542404P | 2004-02-18 | 2004-02-18 | |
| US60/545,542 | 2004-02-18 | ||
| US60/545,424 | 2004-02-18 | ||
| PCT/US2004/011062 WO2004091500A2 (en) | 2003-04-10 | 2004-04-09 | Delivery of immune response modifier compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2521529A1 true CA2521529A1 (en) | 2004-10-28 |
Family
ID=35519615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002521529A Abandoned CA2521529A1 (en) | 2003-04-10 | 2004-04-09 | Irm-support complexes comprising immune response modifiers attached to macromolecular support material |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2521529A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1874345A2 (en) * | 2005-04-25 | 2008-01-09 | 3M Innovative Properties Company | Immunostimulatory compositions |
| WO2012090005A1 (en) * | 2010-12-29 | 2012-07-05 | Imperial Innovations Limited | Agonists of toll like receptor for treating cardiovasuclar disease and obesity |
-
2004
- 2004-04-09 CA CA002521529A patent/CA2521529A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1874345A2 (en) * | 2005-04-25 | 2008-01-09 | 3M Innovative Properties Company | Immunostimulatory compositions |
| EP1874345A4 (en) * | 2005-04-25 | 2008-12-24 | 3M Innovative Properties Co | Immunostimulatory compositions |
| WO2012090005A1 (en) * | 2010-12-29 | 2012-07-05 | Imperial Innovations Limited | Agonists of toll like receptor for treating cardiovasuclar disease and obesity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7923560B2 (en) | Delivery of immune response modifier compounds | |
| AU2005244260B2 (en) | Methods, compositions, and preparations for delivery of immune response modifiers | |
| EP1844201B1 (en) | Aqueous gel formulations containing immune response modifiers | |
| EP1651190B1 (en) | Formulations containing an immune response modifier | |
| JP2006523212A (en) | Diagnosis method of skin lesion | |
| JP3716344B2 (en) | Polyphosphazene derivatives | |
| US8557838B2 (en) | Immune response modifier formulations containing oleic acid and methods | |
| ES2357726T3 (en) | LENSES COVERED. | |
| WO2006063158A3 (en) | Use of supercritical fluids to incorporate biologically active agents into nanoporous medical articles | |
| JP2007503268A (en) | Delivery of immune response modifying compounds | |
| CA2614495C (en) | Drug delivery system | |
| WO2005058415A3 (en) | Implantable medical device having pre-implant exoskeleton | |
| US7563454B1 (en) | Coatings for implantable medical devices | |
| JP2005517490A (en) | Composite stent with polymeric covering and bioactive coating | |
| WO2012058274A2 (en) | Coatings and methods for controlled elution of hydrophilic active agents | |
| JP2007181692A (en) | Tri-branched biologically active copolymer | |
| CA2521529A1 (en) | Irm-support complexes comprising immune response modifiers attached to macromolecular support material | |
| MX2008010860A (en) | Immune response modifier formulations containing oleic acid and methods. | |
| Kim et al. | Intelligent Drug Delivery Systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20130913 |